Non-HLA antibodies in kidney transplantation: comprehensive insights and clinical implications (notice n° 2083208)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03732cam a2200313 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260405005353.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Ratbi, Oumayma |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Non-HLA antibodies in kidney transplantation: comprehensive insights and clinical implications |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2026.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 6 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | While HLA donor-specific antibodies (DSAs) are the primary mediators of allograft rejection, 20-30% of antibody-mediated rejection (ABMR) episodes occur in their absence. These ‘DSA-negative’ rejections represent a significant clinical challenge. This review explores the role of non-HLA antibodies (n-HLab) as potential markers of unexplained graft injury. Pathophysiologically, ischemia-reperfusion injury and endothelial stress trigger the release of cryptic autoantigens, transforming the allograft into a source of self-antigens. Key targets include AT1R, ETAR, LG3, vimentin, and MICA. While observational studies show an association between these antibodies and severe vascular rejection, a causal link and the therapeutic impact of their removal remain undefined. Currently, there is no definitive evidence that monitoring or therapeutically targeting n-HLab translates into improved long-term clinical outcomes. Diagnosis is currently limited by a lack of standardized assays and consensus thresholds. Management remains largely empirical. In conclusion, while n-HLab represent a promising area for risk stratification, further research and clinical validation are required before their routine implementation in clinical practice can be recommended. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Si les anticorps anti-HLA spécifiques du donneur (DSA) constituent les principaux médiateurs du rejet d’allogreffe, 20 à 30 % des épisodes de rejet médié par les anticorps (ABMR) surviennent en leur absence. Ces rejets dits « DSA-négatifs » représentent un défi clinique majeur. Cette revue explore le rôle des anticorps non-HLA (n-HLab) en tant que marqueurs des lésions tissulaires inexpliquées du greffon. Sur le plan physiopathologique, les lésions d’ischémie-reperfusion et le stress endothélial déclenchent la libération d’auto-antigènes cryptiques via des exosomes et des corps apoptotiques. Ce processus transforme l’allogreffe en une source d’auto-antigènes, alimentant ainsi un cycle d’auto-immunité. Les principales cibles antigéniques incluent des récepteurs couplés aux protéines G (RCPG) tels que l’AT1R et l’ETAR, des protéines matricielles comme le LG3 et la vimentine, ainsi que des antigènes polymorphes tels que le MICA. Bien qu’associés aux rejets, leur causalité et l’impact thérapeutique de leur déplétion restent indéfinis. Le diagnostic manque de tests standardisés et de seuils consensuels. Actuellement, aucune preuve ne démontre que leur ciblage améliore la survie à long terme. Leur utilisation en routine n’est donc pas établie, mais ils constituent un axe de recherche majeur pour la stratification des risques. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anticorps non HLA (n-HLab) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | lésion endothéliale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | rejet médié par les anticorps (ABMR) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | transplantation rénale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | antibody-mediated rejection (ABMR) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | endothelial injury |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | kidney transplantation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | non-HLA antibodies (n-HLab) |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yakhlef, Imane |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ouadghiri, Sanae |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | ATOUF, O. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Admou, Brahim |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Annales de Biologie Clinique | 84 | 1 | 2026-03-26 | p. 22-33 | 0003-3898 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-annales-de-biologie-clinique-2026-1-page-22?lang=en&redirect-ssocas=7080">https://stm.cairn.info/revue-annales-de-biologie-clinique-2026-1-page-22?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux